

New: 4th Quarter 2023 Injectable Medication HCPCS/DOFR Crosswalk

Use the updates for dates of service on and after February 7, 2024

On October 10, 2023, the Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates, effective February 7, 2024, are listed on pages 3-4 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net* and CalViva Health *Provider Participation Agreement (PPA)*.

The update includes:

- 16 new injectable medications to be added to the DOFR crosswalk.
- 16 updates and changes to injectable medication procedure codes.
- 2 updates for new generic drugs.

Additional information

Relevant sections of the provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library after logging in to the provider portal at provider.healthnetcalifornia.com > *Provider Library* under Quick Links or at providerlibrary.healthnetcalifornia.com.

If you have questions regarding the information contained in this update, contact CalViva Health at 888-893-1569.

THIS UPDATE APPLIES TO:

- Participating Physician Groups

PROVIDER SERVICES

888-893-1569

www.healthnet.com

PROVIDER PORTAL

provider.healthnetcalifornia.com

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved by the P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. The P&T Committee members include physicians and representatives from participating physician groups (PPGs).

New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
90381	Beyfortus™	Nirsevimab-alip intramuscular (IM) injection solution prefilled syringe 100 mg/ml	Therapeutic injection	
90380	Beyfortus™	Nirsevimab-alip intramuscular (IM) injection solution prefilled syringe 50 mg/ml	Therapeutic injection	
J3590	Columvi™	Glofitamab-gxbm injection for intravenous (IV) infusion	Therapeutic injection	Chemotherapy ¹
J3590	Daxxify®	DaxibotulinumtoxinA-lanm for injection, for intramuscular use	Therapeutic injection	
J9999	Elrexfio™	Elranatamab-bcmm subcutaneous solution 44 mg/1.1ml	Therapeutic injection	Chemotherapy ¹
J3490	Eylea® HD	Aflibercept Injection 8 mg	Therapeutic injection	
J3490	Izervay™	Avacincaptad pegol intravitreal solution 2 mg/0.1ml (20 mg/ml)	Therapeutic injection	
J3490	Ngenla™	Somatrogon-ghla injection, for subcutaneous use	Self-injectable	
J0349	Rezzayo™	Rezafungin for injection, for intravenous use	Therapeutic injection	
J2794	Rykindo®	Risperidone for extended-release injectable suspension, for intramuscular use	Therapeutic injection	
J9999	Talvey™	Talquetamab-tgvs injection, for subcutaneous use	Therapeutic injection	Chemotherapy ¹
J9273	Tivdak®	Tisotumab vedotin-tftv for injection 40 mg	Therapeutic injection	Chemotherapy ¹
J3590	Veopoz™	Pozelimab-bbfg injection solution	Therapeutic injection	
J3590	Vyvgart® Hytrulo	Efgartigimod alfa and hyaluronidase-qvfc injection, for subcutaneous use	Therapeutic injection	
J9332	Vyvgart®	Efgartigimod alfa-fcab injection, for intravenous use	Therapeutic injection	
J3490	Xacduro®	Sulbactam sodium & durlobactam sodium co-packaged For IV solution 1-1 gm	Therapeutic injection	

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following table are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
J9029	Adstiladrin®	Injection, nadofaragene firadenovec-vncg, per therapeutic dose	Replaces J3590
C9152	Abilify asimtufii®	Aripiprazole intramuscular (IM) emergency (ER) suspension prefilled syringe	Replaces J0401
J0802	Acthar® HP	Corticotropin injection, 40 mg	Replaces J0800
J0801	Acthar® HP	Corticotropin injection, 80 mg	Replaces J0800
J7214	Altuviiiio™	Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl	Replaces J0401
C9153	Barhemsys®	Amisulpride (antiemetic) IV solution 10 mg/4ml	Replaces J3490
90375	Bayrab®	Rabies Immune Globulin (R IG), human, for intramuscular and/or subcutaneous use	No longer manufactured
C9155	Epkinly™	Epcoritamab-bysp injection for subcutaneous (SC) use.	Replaces J9999
J0174	Leqembi™	Lecanemab-irmb injection, for intravenous use	Replaces J3590
Q2049	Lipo-dox®	Injection, doxorubicin hydrochloride, liposomal, imported Lipo-Dox	No longer manufactured
C9157	Qalsody™	Tofersen Intrathecal solution 100 mg/15ml (6.7 mg/ml)	Replaces J3490
J3590	Rocktavian™	Valoctocogene roxaparvovec-rvox	Adding HCPCS Code
J2781	Syfovre™	Pegcetacoplan injection, for intravitreal use	Replaces J3490
C9158	Uzedy™	Risperidone subcutaneous emergency (ER) suspension prefilled syringe 200 mg/0.56ml	Replaces J3490
J2797	Varubi®	Rolapitant HCL intravenous line intravenous (IV) emulsion	No longer manufactured
J9345	Zynyz™	Injection Retifanlimab-dlwr, 1 mg	Replaces J9999

Category changes

The following medications have been approved by the Pharmacy and Therapeutics Committee to correct the Primary Category listed below. These medications were incorrectly reported in the *Injectable Medication HCPCS/DOFR Crosswalk with effective date May 3, 2023*.

HCPCS	Drug name	Generic name	Primary category	
			Incorrectly Reported	Corrected
J0717	Cimzia® prefilled syringe kit 200mg NDC 50474-710-81; 50474-710-79	Certolizumab, 200 mg/mL solution in a single-dose prefilled syringe	Therapeutic injection	Self-injectable
Q5128	Cimerli™	Injection, ranibizumab-eqrn (Cimerli) biosimilar, 0.1 mg	Self-injectable	Therapeutic injection

New generic injectable medications

The following medications have been approved by the Pharmacy and Therapeutics Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table

HCPCS	Drug name	Generic name	Primary category	Secondary category
J9051	Bortezomib	Injection, bortezomib (Maia)	Therapeutic injection	Chemotherapy ¹
J0874	Daptomycin	Injection, daptomycin (Baxter), not therapeutically equivalent to J0878	Therapeutic injection	Home health/infusion ²

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

²When administered by a nurse in a home setting.